Swedbank’s Sarepta Therapeutics SRPT Stock Holding History

Swedbank’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-137,400	Closed	-$2.35M	–	692
2025 Q2	$2.35M	Hold	137,400	–	–	﹤0.01%	592
2025 Q1	$8.77M	Hold	137,400	–	–	0.01%	487
2024 Q4	$16.7M	Buy	+137,400	New	+$16.8M	0.02%	383
2023 Q4	–	Sell	-41,245	Closed	-$5M	–	716
2023 Q3	$5M	Hold	41,245	–	–	0.01%	502
2023 Q2	$4.72M	Hold	41,245	–	–	0.01%	528
2023 Q1	$5.68M	Hold	41,245	–	–	0.01%	492
2022 Q4	$5.34M	Hold	41,245	–	–	0.01%	485
2022 Q3	$4.56M	Hold	41,245	–	–	0.01%	512
2022 Q2	$3.09M	Buy	41,245 +1,600	+4%	+$118K	0.01%	561
2022 Q1	$3.1M	Buy	39,645 +15,545	+65%	+$1.19M	0.01%	584
2021 Q4	$2.18M	Hold	24,100	–	–	﹤0.01%	636
2021 Q3	$2.23M	Hold	24,100	–	–	﹤0.01%	636
2021 Q2	$1.87M	Sell	24,100 -4,198	-15%	-$318K	﹤0.01%	655
2021 Q1	$2.11M	Buy	+28,298	New	+$2.61M	﹤0.01%	633

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Swedbank's SRPT Position: Q3 2025 in Review

Swedbank sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 137,400 shares — an estimated $2.35M sold.

Swedbank first reported a position in SRPT in Q1 2021 and held it in 14 quarters. The position peaked at $16.7M in Q4 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Swedbank reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Swedbank sold 137,400 Sarepta Therapeutics shares in Q3 2025, an estimated $2.35M.
Swedbank first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 14 quarters.
Swedbank's Sarepta Therapeutics position peaked at $16.7M in Q4 2024.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Swedbank's 13F filing for Q3 2025, filed 15 Oct 2025.